NASDAQ:IMVT - Immunovant Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.62
  • Forecasted Upside: 250.24 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$10.74
▲ +0.03 (0.28%)
1 month | 3 months | 12 months
Get New Immunovant Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMVT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$37.62
▲ +250.24% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $37.62, with a high forecast of $63.00 and a low forecast of $9.00. The average price target represents a 250.24% upside from the last price of $10.74.

Buy

The current consensus among 13 contributing investment analysts is to buy stock in Immunovant.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/2/2021Credit Suisse GroupBoost Price TargetNeutral$12.00 ➝ $26.00Low
i
6/2/2021SVB LeerinkLower Price TargetOutperform$38.00 ➝ $17.00Medium
i
6/2/2021Robert W. BairdLower Price TargetOutperform$32.00 ➝ $20.00High
i
6/2/2021HC WainwrightLower Price TargetBuy$23.00 ➝ $19.00High
i
6/1/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
6/1/2021GuggenheimDowngradeBuy ➝ NeutralHigh
i
6/1/2021Stifel NicolausDowngradeBuy ➝ Hold$28.00 ➝ $9.00High
i
Rating by Derek Archila at Stifel Nicolaus
5/10/2021HC WainwrightLower Price TargetBuy$33.00 ➝ $23.00High
i
2/16/2021Stifel NicolausReiterated RatingBuy$28.00Low
i
Rating by Derek Archila at Stifel Nicolaus
2/3/2021Raymond JamesLower Price TargetOutperform$58.00 ➝ $35.00Medium
i
2/3/2021SVB LeerinkLower Price TargetOutperform$52.00 ➝ $38.00High
i
2/3/2021HC WainwrightLower Price TargetBuy$54.00 ➝ $33.00High
i
2/2/2021Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
i
2/2/2021Stifel NicolausLower Price TargetBuy$54.00 ➝ $33.00Low
i
1/13/2021HC WainwrightReiterated RatingBuy$54.00High
i
Rating by D. Tsao at HC Wainwright
11/13/2020TruistBoost Price Target$52.00 ➝ $62.00Medium
i
11/13/2020Robert W. BairdBoost Price TargetOutperform$47.00 ➝ $64.00Medium
i
11/13/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $54.00High
i
Rating by D. Tsao at HC Wainwright
11/13/2020SVB LeerinkBoost Price TargetOutperform$39.00 ➝ $52.00High
i
11/12/2020Chardan CapitalBoost Price Target$45.00 ➝ $60.00High
i
Rating by Gbola Amusa at Chardan Capital
10/28/2020UBS GroupInitiated CoverageBuy$61.00Medium
i
10/12/2020GuggenheimInitiated CoverageBuy$63.00Medium
i
10/7/2020Stifel NicolausInitiated CoverageBuy$46.00Medium
i
10/6/2020Lifesci CapitalReiterated RatingOutperformHigh
i
Rating by S. Slutsky at Lifesci Capital
10/2/2020CSFBInitiated CoverageOutperform$49.00High
i
10/2/2020Credit Suisse GroupInitiated CoverageOutperform$49.00High
i
8/26/2020TruistBoost Price Target$36.00 ➝ $52.00Low
i
8/26/2020HC WainwrightReiterated RatingBuy$34.00 ➝ $40.00High
i
Rating by D. Tsao at HC Wainwright
8/25/2020Robert W. BairdBoost Price TargetOutperform$31.00 ➝ $47.00Medium
i
8/25/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$35.00 ➝ $45.00Medium
i
Rating by Gbola Amusa at Chardan Capital
8/24/2020Raymond JamesInitiated CoverageOutperform$35.00High
i
8/20/2020SVB LeerinkBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $34.00Medium
i
Rating by T. Smith at SVB Leerink LLC
8/13/2020Chardan CapitalBoost Price TargetBuy$30.00 ➝ $35.00High
i
Rating by G. Amusa at Chardan Capital
8/5/2020Ci CapitalReiterated RatingBuy$32.00Medium
i
7/29/2020HC WainwrightInitiated CoverageBuy$34.00Medium
i
Rating by D. Tsao at HC Wainwright
6/18/2020SunTrust BanksUpgradeBuyHigh
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
6/17/2020SunTrust BanksBoost Price Target$24.00 ➝ $36.00Low
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/29/2020NomuraBoost Price TargetBuy$27.00 ➝ $37.00High
i
5/29/2020Nomura InstinetBoost Price TargetBuy$27.00 ➝ $37.00High
i
3/4/2020Nomura SecuritiesReiterated RatingBuy$27.00Medium
i
Rating by Christopher Marai at Nomura Securities
2/24/2020SVB LeerinkInitiated CoverageOutperform$24.00High
i
Rating by T. Smith at SVB Leerink LLC
2/17/2020Chardan CapitalReiterated RatingBuyMedium
i
Rating by G. Amusa at Chardan Capital
2/4/2020Nomura SecuritiesInitiated CoverageBuy$27.00High
i
Rating by Christopher Marai at Nomura Securities
1/10/2020SunTrust BanksInitiated CoverageBuy$24.00High
i
1/9/2020Chardan CapitalInitiated CoverageBuy$30.00High
i
1/7/2020Robert W. BairdInitiated CoverageOutperform$21.00Medium
i
(Data available from 6/14/2016 forward)
Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $10.74
$10.64
$11.05

50 Day Range

MA: $14.58
$9.40
$16.76

52 Week Range

Now: $10.74
$9.22
$53.75

Volume

901,306 shs

Average Volume

1,438,916 shs

Market Capitalization

$1.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunovant?

The following equities research analysts have issued research reports on Immunovant in the last twelve months: Chardan Capital, Ci Capital, Credit Suisse Group AG, CSFB, Guggenheim, HC Wainwright, Lifesci Capital, Raymond James, Robert W. Baird, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for IMVT.

What is the current price target for Immunovant?

13 Wall Street analysts have set twelve-month price targets for Immunovant in the last year. Their average twelve-month price target is $37.62, suggesting a possible upside of 250.2%. Guggenheim has the highest price target set, predicting IMVT will reach $63.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $9.00 for Immunovant in the next year.
View the latest price targets for IMVT.

What is the current consensus analyst rating for Immunovant?

Immunovant currently has 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMVT will outperform the market and that investors should add to their positions of Immunovant.
View the latest ratings for IMVT.

What other companies compete with Immunovant?

How do I contact Immunovant's investor relations team?

Immunovant's physical mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company's listed phone number is 917-580-3099. The official website for Immunovant is www.immunovant.com.